{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:52:37Z","timestamp":1780987957428,"version":"3.54.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12185-026-04197-z","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T08:11:13Z","timestamp":1774253473000},"page":"473-475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recent progress in T-cell malignancies including adult T-cell leukemia\u2013lymphoma"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6682-2451","authenticated-orcid":false,"given":"Kisato","family":"Nosaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"4197_CR1","unstructured":"Haematolymphoid Tumours: WHO Classification of Tumours, 5th Edition edn. IARC, Lyon, France. 2024."},{"key":"4197_CR2","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140:1229\u201353.","journal-title":"Blood"},{"key":"4197_CR3","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124\u201330.","journal-title":"J Clin Oncol"},{"issue":"19","key":"4197_CR4","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","volume":"123","author":"J Iqbal","year":"2014","unstructured":"Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123(19):2915\u201323.","journal-title":"Blood"},{"key":"4197_CR5","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s12185-022-03524-4","volume":"117","author":"R Stuver","year":"2023","unstructured":"Stuver R, Lewis N, Dogan A, et al. Moving towards biologically informed treatment strategies for T-cell lymphomas. Int J Hematol. 2023;117:492\u2013503.","journal-title":"Int J Hematol"},{"key":"4197_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s12185-023-03537-7","volume":"117","author":"NE Lewis","year":"2023","unstructured":"Lewis NE, Sardana R, Dogan A. Mature T-cell and NK-cell lymphomas: updates on molecular genetic features. Int J Hematol. 2023;117:475\u201391.","journal-title":"Int J Hematol"},{"key":"4197_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-024-07103-x","volume":"627","author":"M Yamagishi","year":"2024","unstructured":"Yamagishi M, Kuze Y, Kobayashi S, et al. Mechanisms of action and resistance in histone methylation-targeted therapy. Nature. 2024;627:221\u20138.","journal-title":"Nature"},{"key":"4197_CR8","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1111\/cas.15097","volume":"112","author":"S Ito","year":"2021","unstructured":"Ito S, Iwanaga M, Nosaka K, et al. Epidemiology of adult T-cell leukemia-lymphoma in Japan: an updated analysis, 2012\u20132013. Cancer Sci. 2021;112:4346\u201354.","journal-title":"Cancer Sci"},{"key":"4197_CR9","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1111\/cas.14658","volume":"111","author":"Y Imaizumi","year":"2020","unstructured":"Imaizumi Y, Iwanaga M, Nosaka K, et al. Prognosis of patients with adult T-cell leukemia\/lymphoma in Japan: a nationwide hospital-based study. Cancer Sci. 2020;111:4567\u201380.","journal-title":"Cancer Sci"},{"key":"4197_CR10","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s12185-023-03547-5","volume":"117","author":"JI Yasunaga","year":"2023","unstructured":"Yasunaga JI. Viral, genetic, and immune factors in the oncogenesis of adult T-cell leukemia\/lymphoma. Int J Hematol. 2023;117:504\u201311.","journal-title":"Int J Hematol"},{"key":"4197_CR11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1182\/blood.2021013568","volume":"139","author":"Y Kogure","year":"2022","unstructured":"Kogure Y, Kameda T, Koya J, et al. Whole-genome landscape of adult T-cell leukemia\/lymphoma. Blood. 2022;139:967\u201382.","journal-title":"Blood"},{"key":"4197_CR12","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/CCO.0000000000000889","volume":"34","author":"H Kimura","year":"2022","unstructured":"Kimura H, de Leval L, Cai Q, et al. EBV-associated NK and T-cell lymphoid neoplasms. Curr Opin Oncol. 2022;34:422\u201331.","journal-title":"Curr Opin Oncol"},{"key":"4197_CR13","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.annonc.2025.01.023","volume":"36","author":"F d\u2019Amore","year":"2025","unstructured":"d\u2019Amore F, Federico M, de Leval L, et al. Peripheral T-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36:626\u201344.","journal-title":"Ann Oncol"},{"key":"4197_CR14","doi-asserted-by":"crossref","unstructured":"Nizamuddin IA, Mehta-Shah N. BV and beyond: how to incorporate novel agents into PTCL management. Hematology Am Soc Hematol Educ Program. 2024:54\u201361.","DOI":"10.1182\/hematology.2024000530"},{"key":"4197_CR15","doi-asserted-by":"crossref","unstructured":"Dreger P, Schmitz N. The role of stem cell transplant (auto and allo) in PTCL and CTCL. Hematology Am Soc Hematol Educ Program. 2024:69\u201377.","DOI":"10.1182\/hematology.2024000670"},{"key":"4197_CR16","first-page":"2646","volume":"137","author":"N Schmitz","year":"2021","unstructured":"Schmitz N, Truemper L, Bouabdaliah K, et al. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood. 2021;137:2646\u201356.","journal-title":"Blood"},{"key":"4197_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/bmt.2015.265","volume":"51","author":"S Fuji","year":"2016","unstructured":"Fuji S, Fujiwara H, Nakano N, et al. Early application of related SCT might improve clinical outcome in adult T-cell leukemia\/lymphoma. Bone Marrow Transplant. 2016; 51: 205-11.","journal-title":"Bone Marrow Transplant"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04197-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04197-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04197-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:56:37Z","timestamp":1776254197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04197-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4197"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04197-z","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KN: Honoraria; Chugai Pharmaceutical, Kyowa Kirin, Meiji Seika. Bristol Myers Squibb, Abbvie, Daiichi Sankyo. Research funding; Chugai Pharmaceutical. KN is editor of International Journal of Hematology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}